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UNIT A3.5Monitoring Tumor Therapy
This unit presents the preferred set of MR sequences for imaging the brain following the
institution of chemotherapy, radiation therapy, or surgery for brain tumors (see Basic
Protocol 1) and specific modifications will be discussed where necessary (see Basic
Protocol 2). The sequences described in this unit are based on the authors’ experience
with a 1.5 T scanner (Echospeed GE Medical Systems), but can be expected to be equally
applicable to other field strengths and scanners from other manufacturers. Sequences 1
to 5 comprise the preferred Basic Protocol 1.
BASIC
PROTOCOL 1
FOLLOW-UP POST SURGERY
One of the most important issues for initial post-operative MRI of the brain is that it should
be performed within 24 to 48 hr of surgery to assess for any enhancing residual tumor.
Noncontrast T1-weighted images are important to obtain in the same imaging plane as the
post-contrast T1-weighted images to assess for residual tumor and not mistake blood
products for enhancing tumor. Sequences 1 to 5 comprise the preferred protocol.
Table A3.5.1 lists the hardware necessary to perform the procedure, along with appropri-
ate parameters.
NOTE: Be sure that technologists and nurses have immediate access to any equipment
such as crash carts or oxygen that may be necessary in the event of an emergency.
Reactions to contrast agents are rare, but the resources are necessary.
Materials
Intravenous contrast agent (e.g., Magnevist, Omniscan, Prohance)
Normal saline (0.9% NaCl), sterile
Setup patient and equipment
1. Interview (screen) the patient to ensure that he or she has no contraindications to the
MRI examination, such as a cardiac pacemaker or other implants containing ferro-
magnetic materials. Question the patient regarding any health conditions that may
require the presence of specific emergency equipment during the scanning procedure,
or necessitate any other precautions.
Generally standard screening forms are used for all patients scanned in a magnetic
resonance system.
The presence of ferromagnetic metals may be a health hazard to the patient when he or she
is inside the magnet, and will also affect the imaging. If in doubt as to the exact composition
of the items, it is best to exclude patients with any metal implants; see Shellock (1996) for
discussion of what implants may be safely scanned using magnetic resonance.
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Table A3.5.1 Equipment Parameters for Imaging Brain Tumors
Coil type Quadrature head coil
Gradient coil strength 25 mT/m (or whatever the system permits)
Cardiac gating No
Peripheral gating For safety only
Respiratory gating No
Respirator If required by patient
Oxygen If required by patient
Motion cushions No
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Patients may be accompanied into the magnet room by a friend or family member, who can
sit in the room during the scan and comfort the patient as needed. This companion must
be screened as well to ensure the absence of loose metal objects on the body or clothing.
2. If the procedure is a research protocol, have the patient sign any necessary consent
form.
3. Have the patient remove all jewelry and change into a gown to eliminate any metal
that might be found in clothing.
4. Have the patient wash off any mascara and other makeup to avoid local tissue heating
and image artifacts.
5. Inform the patient about what will occur during the procedure, what he or she will
experience in the magnet, and how to behave, including the following:
a. If earphones or headphones are used to protect the ears from the loud sounds
produced by the gradients, the patient will be asked to wear these, but will be able
to communicate with you at any time during the imaging.
b. The patient will be given a safety squeeze-bulb or similar equipment to request
assistance at any time (demonstrate how this works).
c. For good results the patient should not talk, and should avoid or minimize
swallowing or other movement, during each scan—i.e., as long as the banging
sounds continue. Between scans, talking and swallowing are allowed in most
cases, but should be avoided when comparative positional studies are being
performed; the patient will be informed when this is the case.
d. Nevertheless, the patient may call out at any time if he or she feels it necessary.
6. Have the patient mount onto the table in the supine position. Either before or right
after the patient lies down, set up any triggering devices or other monitoring
equipment that is to be used.
7. Center the patient in the head coil at the region where the key information is desired.
Make sure the head and neck are constrained to prevent motion.
Generally the patient’s head is fixed so that the head is horizontal (not tilted) and the neck
and head lie along the axis of the patient table.
8. If needed, place a pillow or other support under the knees to make the patient more
comfortable.
9. Use the centering light to position the patient (centered on the nasion) and put him
or her into the center of the magnet.
Once this step has been performed, so long as the patient does not move on the table, the
table itself can be moved and then replaced in the same position as before without
jeopardizing the positioning of one scan relative to another.
10. If the patient is unable to hold still, provide an appropriate sedative.
Sequence 1: Localizer
11. Run sequence 1 according to Table A3.5.2.
Sequence 2: T1-weighted scan
12. Run sequence 2 according to Table A3.5.3.
Sequence 3: T2-weighted scan
13. Run sequence 3 according to Table A3.5.4.
Sequence 4: Fluid attenuated inversion recovery (FLAIR) scan
14. Run sequence 4 according to Table A3.5.5.
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Table A3.5.3 Primary Clinical Imaging Parameters for Sequence 2
(T1-Weighted)
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 11 msec (or select “minimum
full” echo time)
Receiver bandwidth (RBW) 10 kHz
Repeat time (TR) 500 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time 1 min, 36 sec
Table A3.5.2 Primary Clinical Imaging Parameters for Sequence 1
(T1-Weighted)
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Sagittal
Central slice or volume center Laser light centered on nasion
Echo time (TE) 11 msec (or select “minimum
full” echo time)
Receiver bandwidth (RBW) 10 kHz
Repeat time (TR) 500 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding No
Saturation pulses Not applicable
Scan time 1 min, 36 sec
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Table A3.5.5 Primary Clinical Imaging Parameters for Sequence 4 (Fast
FLAIR)
Patient position Supine
Scan type Inversion recovery fast spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 120 msec (effective)
Receiver bandwidth (RBW) 16 kHz
Echo train length (ETL) 8
Repeat time (TR) 10,000 msec
Inversion time (TI) 2200 msec
Flip angle (FA) 180°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time ∼5 min
Table A3.5.4 Primary Clinical Imaging Parameters for Sequence 3
(T2-Weighted)
Patient position Supine
Scan type Fast spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Laser light centered on nasion
Echo time (TE) 102 msec (effective)
Receiver bandwidth (RBW) 16 kHz
Echo train length (ETL) 8
Repeat time (TR) 3600 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 240 mm, 240 mm
Resolution (∆x, ∆y) 0.94 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 5 mm
Number of slices 20 or as many as needed to cover
the region of interest
Slice gap 2.5 mm
Number of acquisitions (Nacq) 1
Swap read and phase encoding Yes
Saturation pulses Not applicable
Scan time 1 min, 30 sec
Supplement 1 Current Protocols in Magnetic Resonance Imaging
A3.5.4
Monitoring
Tumor Therapy
Sequence 5: Post-contrast imaging
15. Remove the patient from the scanner. The patient should not move on the table.
Establish an intravenous line from which the contrast agent can be injected, and attach
this line securely to the patient so that movement into or out of the magnet will not
pull at the patient’s arm. Move the patient back into the scanner.
It is preferable to insert the line prior to imaging and to leave the patient in the magnet,
with no intervening motion, between the scans run before contrast agent injection and those
run after injection.
16. Leaving the patient in the magnet, inject the contrast agent, flush the line with 10 ml
saline.
A dose of 0.1 mmol/kg of contrast agent is usually given.
A delay in scanning may actually be beneficial when evaluating for metastases, which is
one of the reasons we scan in multiple planes after intravenous contrast administration.
17. Acquire the post-contrast images using the same parameters as sequence 2 (T1-
weighted).
In addition to the transverse plane, the coronal plane is routinely obtained, with the
following changes to the parameters in Sequence 2: (a) flow compensation is on; (b) TE is
20 msec (prolonged due to flow compensation gradients); and (c) it is not necessary to
swap read and phase encoding directions. In patients requiring sedation and in all pediatric
patients, we also routinely obtain a third post-contrast plane of imaging (sagittal).
BASIC
PROTOCOL 2
RADIATION NECROSIS VERSUS TUMOR RECURRENCE
Radiation necrosis and recurrent tumor are indistinguishable by conventional MR tech-
niques and on the basis of paramagnetic enhancement, since both may appear mass like
and enhance in most circumstances (Grossman et al., 1988). The time interval between
radiation therapy and the MR scan is an essential part of making an intelligent presumptive
diagnosis of either radiation necrosis or recurrent tumor (Atlas and Lavi, 1996). Several
studies suggest that proton MR spectroscopy may be a potentially useful method for
differentiating tumor recurrence from radiation necrosis (Taylor et al., 1996; Nelson et
al., 1999; Ricci et al., 2000). Whole brain chemical-shift imaging (CSI) maps may also
be potentially useful in the investigation of brain tumors by providing visual metabolite
maps, rather than spectral data.
Setup patient and equipment
1. Use the same equipment and perform the same setup as for the previous method (see
Basic Protocol 1).
2. Run sequences 1 to 5 (see Basic Protocol 1).
3. Localize the lesion on a transverse image (typically the post-contrast transverse
T1-weighted image).
The voxel placement requires physician input to ensure the correct region of interest is
being studied. Two separate scans are performed: one with the voxel placed over the area
in question (typically the enhancing portion of the lesion), the other scan is performed with
the voxel placed in the contralateral hemisphere (in a “normal appearing” analogous area
of the brain). The screen should always be saved to document placement of the voxel.
Sequence 6: Proton (1H) MR Spectroscopy
The proton brain exam (PROBE) on GE systems is an automated acquisition that is widely
available and is performed using the single voxel technique (8 cm3). A high field system
is required to obtain good spectra. There are 2 possible localization methods: STEAM
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(stimulated-echo acquisition mode) or PRESS (point-resolved spectroscopy). The se-
quence parameters can be set by the user (TR, TE, voxel size). Short TE spectroscopy has
the advantage of providing more information, since more peaks are visible for analysis
and detection of lipid-breakdown products is maximized. Long TE spectra have less
baseline distortion and are easier to quantify. Since there is a √2 decrease in the
signal-to-noise ratio with STEAM sequences, the PRESS sequence is usually preferred.
Spectra obtained following the administration of intravenous contrast may be altered
(Sijens et al., 1997). In particular, studies have shown a mean loss of 15% of the peak area
of choline-containing compounds without significant changes in creatine (Cre) or N-ace-
tyl aspartate (NAA) (Sijens et al., 1997). In routine clinical practice, the spectra are
obtained following the administration of intravenous contrast and the voxel is placed over
the solid (enhancing) portion of the lesion so that theoretically signal is acquired from
viable tumor tissue.
4. Perform automated shimming and water suppression, center the voxel over the
enhancing portion of the lesion, and run sequence 6 according to Table A3.5.6.
5. After completion of the scan, a spectrum will appear on the screen and the values for
the spectrum should be saved.
6. Place the voxel in the contralateral hemisphere and repeat the scan.
7. After completion of the scan, another spectrum will appear on the screen and the
values for the spectrum should be saved.
COMMENTARY
Background Information
Magnetic resonance imaging is a well-es-
tablished tool in the evaluation of brain tumors
by offering superb anatomical detail and tissue
characterization of brain lesions. Conventional
MRI techniques have limitations in the ability
to discriminate between recurrent tumor and
radiation necrosis as well as determining the
exact limits of tumor extension. Postoperative
patients being studied by MRI for evaluation of
residual or recurrent tumor do not pose as
difficult a problem as patients who receive
radiation therapy. Contrast enhanced imaging
is critical to the evaluation of post-therapy brain
tumors. Proton MR spectroscopy may be a
potentially useful tool for differentiating tumor
recurrence from radiation necrosis (Taylor et
al., 1996; Nelson et al., 1999).
Critical Parameters and
Troubleshooting
A critical component of the MR examina-
tion is an adequate history of the therapeutic
intervention instituted. Precontrast T1-
weighted images frequently demonstrate sub-
acute blood products and need to be carefully
Table A3.5.6 Primary Clinical Imaging Parameters for Sequence 6 (1H MR
Spectroscopy)
Patient position Supine
Scan type PROBE
Voxel Center See text (steps 4 and 6)
Echo time (TE) 35 msec and 144 msec
Repeat time (TR) 2000 msec
Flip angle (FA) 90°
Voxel size (∆x, ∆y, ∆z) 2 cm, 2 cm, 2 cm
Number of acquisitions (Nacq) 8a and 128b
Saturation pulses Water
Scan time ∼5 min
aWithout water suppression.
bWith water suppression.
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compared with post-contrast images to assess
for enhancing portions of the area of interest.
In pediatric patients and other subjects requir-
ing sedation, 3 planes (transverse, coronal,
sagittal) of imaging should be obtained in the
post-contrast acquisition. Post-operative imag-
ing in brain tumors should ideally be performed
within 24 to 48 hr of the operation. Long-term
follow-up imaging relies on the availability of
prior imaging studies for comparison, and his-
tory regarding treatment protocols.
Proton MR spectroscopy studies have
shown that contrast administration will alter
spectra by decreasing the peak area of choline-
containing compounds. Tumors are frequently
heterogeneous histologically and placement of
the voxel in different regions of the tumor may
yield different MR spectroscopy results. The
relatively large voxel size also results in volume
averaging with the adjacent brain. In routine
clinical use, the post-contrast images are used
to identify the solid appearing portion of the
lesion and the voxel is placed in the solid
(enhancing portion) of the lesion (Ricci et al.,
2000).
Anticipated Results
The goal in evaluating post-therapy brain
tumors is to image and localize the site of
documented tumor and assess for residual/re-
current tumor. The dilemma of distinguishing
radiation necrosis from residual/recurrent tu-
mor remains. Correlation with the timing of a
given tumor therapy is helpful, however fre-
quently a tissue biopsy is needed to solve the
issue.
Time Considerations
The Basic Protocol 1 should take ∼30 min
to complete. Proton MR spectroscopy (see Ba-
sic Protocol 2) adds ∼10 to 15 min to the
imaging session.
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